REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Baseline characteristics1

REVLIMID was studied in lower-risk del 5q transfusion-dependent patients (N=148)

The primary trial endpoint in the major study was RBC transfusion independence in del 5q MDS.18

Explore Efficacy